Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

Survival time

Survival time

CONTACT US

Summary

The goal of this study is to determine the safety and efficacy of dendritic cell (DC)-based immunotherapy targeting synthesized peptides, Wilms tumor 1 (WT1) and Mucin 1, cell surface associated (MUC1) for biliary tract cancers (BTCs). The results suggest the therapy was safe and produced a clinical response for patients who had chemotherapy.

Patients characteristics

65 patients who had nonresectable, recurrent or metastatic Biliary tract cancer ages 46-86 years old with median age of 68.0 (13 patients with intrahepatic cholangiocarcinoma, 30 patients with extrahepatic cholangiocarcinoma, 22 patients with gallbladder cancer).

Methodology

• Peripheral blood mononuclear cells were prepared from leukapheresis by Ficoll-Hypaque gradient density centrifugation
• PBMCs were attached to tissue culture plates and were continuously cultured in medium containing GM-CSF 50ng/mL, and IL-4 25ng/mL to generate immature DCs for 5 days.
• Immature DCs were stimulated by OK-432 and Prostaglandin E2 (50ng/mL) for 24 hours.
• At day 7 of culture, the DC were pulsed with the major histo- compatibility complex-1-restricted WT1 peptide antigens.

Treatment

All patients were injected 5 to 7 times intradermally (ID) with DC about (107 cells/injection) in close proximately to axial lymph nodes at interval of approximately 14-21 days. OK-432 was simultaneously administered with the DC vaccine as an immunological adjuvant in the patients with had no drug allergy.

Results

• 55% of all of the patient had common adverse event reaction in the injection site. And fever 23%.
• No serious treatment related adverse events was observed during the vaccination.
• The MST from diagnosis was 18.5 months and from the first vaccination was 7.2 months
• The 1 year survival rate from diagnosis was 69% while 2 year survival was 31%
• At 3 months after the vaccination, none of all 65 patients showed complete remission (CR). However, 4 patients (6%) had partial response (PR), and 15 patients had stable disease (SD) and 44 patients (67.7%) had progressive disease (PD)
• 4 patients survived for more than 20 months and 1 patient survived for 32 months.
• The MST from the first vaccine with Chemotherapy was 8.2 months and without Chemotherapy was 5.3 months.

Conclusion

DC-based immunotherapy targeting WT1 and/or MUCI was safe and produced a clinical response. DC vaccine was well tolerated in all patients and there were no serious complications. DC-based immunotherapy produced a clinical response for the patients who underwent chemotherapy and maintained good nutrition status.

Article Reference link: click here

Scientific article publishing date: 7/5/2013

Immucura identifier BSC21_324EN

ALL SCIENTIFIC PAPERS
CONTACT US